Skip to main content
Smart Investors Daily
SB

NASDAQ · SBTX

Silverback Therapeutics, Inc.

Healthcare · Biotechnology

$5.87

Up+$0.06 (+1.03%)

Updated Aug 22, 2026, 11:02 PM

SID Score

Composite research score

Smart Money

Institutional and insider signal

Market cap
550.43M
P/E ratio
-13.85
Dividend yield
0.00%
52-week range
— – —
Volume
116.69K
Avg. volume
172.78K

Price performance

SBTX price history

1M range · 0 trading sessions · Daily adjusted prices

SBTX does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SBTX news

The latest Smart Investors Daily articles mentioning SBTX.

SBTX research

Overview

Company profile and research snapshot.

Company profile

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
SBTX recent ratings
DateFirmRatingTarget
Apr 4, 2022Goldman SachsNeutral
Apr 1, 2022StifelHold
Apr 1, 2022HC Wainwright & Co.Neutral
Apr 1, 2022SVB LeerinkMarket Perform
Apr 1, 2022JonesTradingHold
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Apr 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022

Upgrades According to Scotiabank, the prior rating for Welltower Inc (NYSE:WELL) was changed from Sector Perform to Sector Outperform. In the fourth quarter, Welltower showed an EPS of $0.83, compared to $0.84 from the year-ago quarter. The stock has a 52-week-high of $98.47 and a 52-week-low of $70.74. At the end of the last trading period, Welltower closed at $97.82. According to B of A Securities, the prior rating for SunPower Corp (NASDAQ:SPWR) was changed from Underperform to Neutral. In the fourth quarter, SunPower showed an EPS of $0.07, compared to $0.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $35.00 and a 52-week-low of $14.00. SunPower closed at $21.41 at the end of the last trading period. For Leslies Inc (NASDAQ:LESL), Goldman Sachs upgraded the previous rating of Neutral to Buy. For the first quarter, Leslies had an EPS of $0.06, compared to year-ago quarter EPS of $0.06. The current stock performance of Leslies shows a 52-week-high of $31.55 and a 52-week-low of $18.14. Moreover, at the end of the last trading period, the closing price was at $20.15. For Ollie's Bargain Outlet Holdings Inc (NASDAQ:OLLI), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. For the fourth quarter, Ollie's Bargain Outlet had an EPS of $0.69, compared to year-ago quarter EPS of $0.97. At the moment, the stock has a 52-week-high of $98.58 and a 52-week-low of $37.67. Ollie's Bargain Outlet closed at $42.85 at the end of the last trading period. For NIO Inc (NYSE:NIO), UBS upgraded the previous rating of Neutral to Buy. NIO earned $0.16 in the fourth quarter, compared to $0.14 in the year-ago quarter. The current stock performance of NIO shows a 52-week-high of $55.13 and a 52-week-low of $13.01. Moreover, at the end of the last trading period, the closing price was at $21.93. Evercore ISI Group upgraded the previous rating for DCP Midstream LP (NYSE:DCP) from In-Line to Outperform. In the fourth quarter, DCP Midstream showed an EPS of $1.44, compared to $0.34 from the year-ago quarter. The stock has a 52-week-high of $36.71 and a 52-week-low of $21.32. At the end of the last trading period, DCP Midstream closed at $33.16. JP Morgan upgraded the previous rating for Zebra Technologies Corp (NASDAQ:ZBRA) from Neutral to Overweight. Zebra Technologies earned $4.54 in the fourth quarter, compared to $4.46 in the year-ago quarter. The current stock performance of Zebra Technologies shows a 52-week-high of $615.00 and a 52-week-low of $375.63. Moreover, at the end of the last trading period, the closing price was at $413.73. See all analyst ratings upgrades. Downgrades Chardan Capital downgraded the previous rating for Kaleido Biosciences Inc (NASDAQ:KLDO) from Buy to Neutral. For the third quarter, Kaleido Biosciences had an EPS of $0.54, compared to year-ago quarter EPS of $0.65. The current stock performance of Kaleido Biosciences shows a 52-week-high of $9.47 and a 52-week-low of $1.30. Moreover, at the end of the last trading period, the closing price was at $1.70. JP Morgan downgraded the previous rating for Gold Fields Ltd (NYSE:GFI) from Overweight to Neutral. NoneThe current stock performance of Gold Fields shows a 52-week-high of $17.20 and a 52-week-low of $7.75. Moreover, at the end of the last trading period, the closing price was at $16.12. B of A Securities downgraded the previous rating for Sportradar Group AG (NASDAQ:SRAD) from Buy to Neutral. At the moment, the stock has a 52-week-high of $28.22 and a 52-week-low of $11.06. Sportradar Gr ...Full story available on Benzinga.com

Benzinga · Dec 16, 2021

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug Calliditas Therapeutics AB (publ)'s (NASDAQ: CALT) announced the U.S. Food and Drug Administration has approved Tarpeyo delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. This indication is approved under accelerated approval. It has not been established whether Tarpeyo slows kidney function decline in patients with IgAN. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. The stock was surging 41.2% to $26.32 in premarket trading. Mesoblast Says FDA Agrees On Additional Trial That Could Potentially Lead To Approval Of Stem Cell Therapy For Low Back Pain Following the receipt of feedback from FDA's Office Of Tissues And Advanced Therapies, Mesoblast Ltd (NASDAQ: MESO) said it plans to conduct an additional U.S. Phase 3 trial for its stem cell therapy rexlemestrocel-L in patients with chronic low back pain due to degenerative disc disease refractory to available therapies, including opioids. The additional trial may support submissions for potential approval in both the U.S. and EU. Cumulative milestone payments could reach $1 billion depending on the final outcome of Phase 3 studies and patient adoption. Mesoblast will also receive tiered double-digit royalties on product sales. The stock was adding 9.66% to $5.45 in premarket trading. Biogen Announces Schedule For Aduhelm Post-Marketing Study Biogen, Inc. (NASDAQ: BIIB) and Eisai Co., Ltd. (PNK: ESALY) provided an update on the continuing progress of the Phase 4 post-marketing confirmatory study of Aduhelm. The companies anticipate submitting the final protocol for review to the FDA in March 2022, with the initiation of patient screening in May 2022. The primary completion date is expected to be approximately four years after the study begins. The trial will also include a long-term extension to collect longer-term treatment data for up to 48 months. Novartis To Buy Back $15B In Stock Novartis AG (NYSE: NVS) announced that it will initiate a share buyback of up to $15 billion to be executed by the end of ...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.